IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

NCT07722494 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

550

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: IBI363 + bevacizumab
DRUG: Investigator's choice of therapy

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.